Breaking Finance News

A statement released earlier today by Zacks Investment Research about Oncobiologics Inc (NYSE:ONS) bumps the target price to $1.50

Boasting a price of $1.18, Oncobiologics Inc (NYSE:ONS) traded -2.94% lower on the day. With the last close down -29.69% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the date range. Oncobiologics Inc has recorded a 50-day average of $1.74 and a two hundred day average of $2.35. Volume of trade was down over the average, with 144,895 shares of ONS changing hands under the typical 485,100

Zacks Investment Research bumped up the target of Oncobiologics Inc (NYSE:ONS) to $1.50 stating a potential upside of 0.27%.

Performance Chart

Oncobiologics Inc (NYSE:ONS)

With a total market value of $0, Oncobiologics Inc has with a one year low of $1.65 and a one year high of $4.78 .

More About Oncobiologics Inc (NYSE:ONS)

Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company's other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *